410 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-5667
Assistant Professor, Infectious Diseases
Physician, FGP-Infectious Diseases
|2013 - present||Janani Singaravelu, Ohio State University Wexner Medical Center.|
|2013 - present||Janani Singaravelu Ohio State University Wexner Medical Center.|
|2008 - present||Internal Medicine: American Board of Internal Medicine|
|2010 - present||Doctor of Medicine: State Medical Board of Ohio|
|2010 - present||Infectious Diseases: American Board of Internal Medicine|
|1996||B.S., University of Maryland|
|2002||Ph.D., University of Maryland School of Medicine|
|2004||M.D., University of Maryland School of Medicine|
|2008 - present||Journal of the American Medical Association|
|2011 - present||Environmental Health Perspectives|
|1993 - present||National Institu*e of General Medical Sciences. *.|
|1994||Howard Hughes Summer Research Award. *.|
|1995||Index Book Award for excellence in the study of chemistry. Merck.|
|1995||College Park Senior Summer Scholar. University of Maryland.|
|1996||Student Award. American Institute of Chemists.|
|2007||Resident of the Year. York Hospital.|
|2008||Travel Award. Society for Healthcare Epidemiology of America.|
|2008||Infectious Diseases Fellows Travel Grant. ICAAC/IDSA.|
Lustberg,M; Silbergeld,E. "Blood lead levels and mortality." ARCHIVES OF INTERNAL MEDICINE. Vol. 162, no. 21. (November 2002.): 2443-2449.
Weaver,V,M; Schwartz,B,S; Ahn,K,D; Stewart,W,F; Kelsey,K,T; Todd,A,C; Wen,J,Y; Simon,D,J; Lustberg,M,E; Parsons,P,J; Silbergeld,E,K; Lee,B,K. "Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers." ENVIRONMENTAL HEALTH PERSPECTIVES. Vol. 111, no. 13. (October 2003.): 1613-1619.
Nash D, Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann RB, Silbergeld EK.. "Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women.." JAMA. Vol. 289, no. 12. (March 2003.): 1523-1532.
Theppeang,K; Schwartz,B,S; Lee,B,K; Lustberg,M,E; Silbergeld,E,K; Kelsey,K,T; Parsons,P,J; Todd,A,C. "Associations of patella lead with polymorphisms in the vitamin D receptor, delta-aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes." JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE. Vol. 46, no. 6. (June 2004.): 528-537.
Lustberg,M,E; Schwartz,B,S; Lee,B,K; Todd,A,C; Silbergeld,E,K. "The G(894)-T-894 polymorphism in the gene for endothelial nitric oxide synthase and blood pressure in lead-exposed workers from Korea." JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE. Vol. 46, no. 6. (June 2004.): 584-590.
Weaver,V,M; Schwartz,B,S; Jaar,B,G; Ahn,K,D; Todd,A,C; Lee,S,S; Kelsey,K,T; Silbergeld,E,K; Lustberg,M,E; Parsons,P,J; Wen,J,Y; Lee,B,K. "Associations of uric acid with Polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers." ENVIRONMENTAL HEALTH PERSPECTIVES. Vol. 113, no. 11. (November 2005.): 1509-1515.
Lustberg,M,E. "Febuxostat versus allopurinol for gout." NEW ENGLAND JOURNAL OF MEDICINE. Vol. 354, no. 14. (April 2006.): 1532-1532.
Weaver VM, Lee BK, Todd AC, Ahn KD, Shi W, Jaar BG, Kelsey KT, Lustberg ME, Silbergeld EK, Parsons PJ, Wen J, Schwartz BS.. "Effect modification by delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers.." Environ Res.. Vol. 102, no. 1. (September 2006.): 61-69.
Uradomo LT, Lustberg ME, Darwin PE.. "Effect of physician training on fluoroscopy time during ERCP.." Dig Dis Sci.. Vol. 51, no. 5. (May 2006.): 909-914.
Lustberg,Mark,E. "Shock as a covariate in a study of treatment of methicillin-resistant Staphylococcus aureus bacteremia." CLINICAL INFECTIOUS DISEASES. Vol. 46, no. 9. (May 2008.): 1483-1483.
Lustberg,Mark,E; Schlesinger,Larry,S; Mangino,Julie,E. "Concerns about "Complicated Skin and Skin-Structure Infections and Catheter-Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study"." CLINICAL INFECTIOUS DISEASES. Vol. 49, no. 2. (July 2009.): 313-313.
Lustberg MB, Bekaii-Saab T, Kolesar J, Young D, Otterson G, McCracken B, Lustberg ME, Villalona-Calero MA. "Phase II Randomized Study of Sequentially Administered Mitomycin C (MMC) and Irinotecan (CPT-11) in Patients with Advanced Esophageal and Gastroesophageal Adenocarcinoma (OSU 0151).." J Thorac Oncol.. Vol. 5, no. 5. (May 2010.): 713-718.
Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston, Byrd C, and Blum K.. "Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma." Cancer - PMCID: 3116936. (December 2010.): -.
Baiocchi,Robert,A; Alinari,Lapo; Lustberg,Mark,E; Lin,Thomas,S; Porcu,Pierluigi; Li,Xiaobai; Johnston,Jeffrey,S; Byrd,John,C; Blum,Kristie,A. "Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma." CANCER. Vol. 117, no. 11. (June 2011.): 2442-2451.
Alinari,Lapo; Yu,Bo; Christian,Beth,A; Yan,Fengting; Shin,Jungook; Lapalombella,Rosa; Hertlein,Erin; Lustberg,Mark,E; Quinion,Carl; Zhang,Xiaoli; Lozanski,Gerard; Muthusamy,Natarajan; Praetorius-Ibba,Mette; O'Connor,Owen,A; Goldenberg,David,M; Byrd,John,C; Blum,Kristie,A; Baiocchi,Robert,A. "Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma." BLOOD. Vol. 117, no. 17. (April 2011.): 4530-4541.
Stevenson KB, Balada-Llasat JM, Bauer K, Deutscher M, Goff D, Lustberg M, Pancholi P, Reed E, Smeenk D, Taylor J, West J. "The economics of antimicrobial stewardship: the current state of the art and applying the business case model." Infect Control Hosp Epidemiol. Vol. 33, no. 4. (April 2012.): 389-97.
Ramaswamy,Bhuvaneswari; Phelps,Mitch,A; Baiocchi,Robert; Bekaii-Saab,Tanios; Ni,Wenjun; Lai,Ju-Ping; Wolfson,Anna; Lustberg,Mark,E; Wei,Lai; Wilkins,Deidre; Campbell,Angela; Arbogast,Daria; Doyle,Austin; Byrd,John,C; Grever,Michael,R; Shah,Manisha,H. "A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors." INVESTIGATIONAL NEW DRUGS. Vol. 30, no. 2. (April 2012.): 629-638.
Exline MC, Ali NA, Zikri N, Mangino JE, Torrence K, Vermillion V, St Clair J, Lustberg ME, Panchili P, Sopirala MM. "Bryond the bundle - journey of a tertiary care medical intensive care unit to zero central line-assoicated bloodstream infections.." Crit Care. Vol. 17, no. 2. (March 2013.): R41-.
Lustberg ME, Bauer KA. "How much is a life worth, Food for thought.." Clinical Infectous Diseases. Vol. Epub doi: 10.1093/cid/cit311, (May 2013.): *-.
Sopirala,MM, Smyer J, Fawley L, Mangino JE, Lustberg ME, Lu J, Chucta S, Crouser ED. "Sustained reduction of central line assoicated bloodstream infections in an intensive care unitusing a top-down and bottom-up approach.." American Journal of Infection Control. Vol. 41, no. 2. (February 2013.): 183-184.
Abandeh FI, Lustberg ME, Devine S, Elder P, Andritsos L, Martin SI. "Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case Control Study." Bone Marrow Transplantation. -.
|August 2000||Lustberg, M and Silbergeld E."Blood lead and mortality in the National Health and Nutritional Examination Survey II (NHANES II) cohort" Ann Arbor.|
|June 2002||Lustberg M and Silbergeld E."Lead and Mortality in the United States, Attributable Risk" Palm Desert.|
|October 2008||Lustberg ME, Goff DA, Pancholi P., Mangino JE."Outcomes in patients with MRSA bacteremia and reduced susceptibility and reduced susceptibility to vancomycin" *.|
|September 2008||Bauer K, Lustberg M, West J, Taylor J, Goff DA, Stevenson K."An evaluation of cefepime Food and Drug Administration (FDA) early alert warning on patient outcomes" *.|
|March 2009||Lustberg ME, Goff DA, Mangino JE."The effect of Infectious Disease consultation on management, outcomes and cost of methicillin resistant Staphylococcus aureus acteremia." *.|
|July 2009||Martin SI, Lustberg M, Davis J, Maher W, Koletar S."Measuring Medical Knowledge at the Inition of Infectious Diseases Fellowship Training" Columbus.|
|April 2010||Yan F, Alinari L, Lustberg M, Martin KL, Nowicki O, Wu X, Yu B, et al."Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expresion in high grade astrocytomas." Washington, DC.|
|December 2011||Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas DMm Grever MR, baiocchi RA."Silvestrol Modulates Direct Anti-tumor Activity Against Epstein-Barr Virus (EBV) Associated Lymphomas while Sparing Innate and Antigen Specific Adaptive Immunity" San Diego.|
|December 2011||Martin LK, Lustberg ME, Yan F, Patton JT, Porcu P, Nuovo G, Vavaliere R, Baiocchi RA."Successful Treatmetn of Primary Central Nervous System Post Transplant Lymphoproliferative Disorder (PCNS-PTLA) with Zidovudine (AZT), Ganciclovir (GCV), Tituximab and Dexamethasone: A single-Institution Case Series." San Diego.|
|December 2011||Lustberg ME, Pelletier R, Porcu P, Martin S, Baiocchi RA."Risk Factors for Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients" San Diego.|
|October 2012||Zikri N, Exline M, Mangino J, Ali N, Torrence K Vermillion B, St Clair J, Lustberg M, Pancholi P, Spoirala M."Beyond the Bundle: Role of the Environment in Central Line Associated Blood Stream Infections." San Diego.|
|October 2012||Abandeh F, Lustberg M, Devine S, Elder P, Andritsos L, Martin S."Stem Cell Transplant (SCT) Recipients with Rhinovirus Infection: A Matched, Case-Control Study." San Diego.|
|November 2012||Hofmeister CC, Bowers MA, Bingman A, Lozanski G, Baiocchi RA, et al."Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Mulitple Myeloma" San Diego.|
|November 2012||Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu P, Penza S, Greenfield CN, Sell M, Earl CT, Zitesman J, Quinion C, Lustberg ME, Andritsos LA, and Devine SM.."Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance." San Diego.|
|November 2012||Alinari L, Uan F, Smith P, Patton JT, Quinion C, Yu B, Earl CT, Lustberg ME, et al."Protein Arginine Methyltransferase 5 (PRMT5) Over Expression IS Essential for Epstein-Barr Virus DRiven B Cell Transformation" San Diego.|
|2010 - present||Judged medical student clinical vignettes presented in poster form. Ohio American College of Physician's. Columbus, OH.|
|2000 - 2001||University of Maryland Graduate Student Association. Treasurer.|
Yan F, Alinari L, Lustberg M, Martin LK, et al. Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas. January 2013.
Patton JT, Lustberg ME, Garman SL, et al. Silvestrol Modulates Direct Anti Tumor Activity Against Epstein-Varr Virus (EBV)-Assocaited Lymphomas while Sparing Innate and Antigen Specific Adaptive Immunity. January 2013.
Lustberg ME, Pelletier R, Pierluigi P., Martin SI, Quinion CD, Caligiuri MA, Baiocchi RA. Immunogenetic risk factors and clinical outcomes in patients with post transplant lymphoproliferative disorder. January 2013.
Martin LK, Lustberg ME, Yan F, Patton JT, Porcu P, et al. Successful Tratment of Primary Central Nervous System Post Transplant Lymphoproliferative Disorder (PCNS-PTLD) with Zidovudine (AZT), Ganciclovir (GCV), Rituximab and Dexamethasone: A Single Institution Case Series.
Lustberg ME, Weber D, Singaravelu J, Baiocchi RA, Martin SI, Pelletier R. Immunogenetic risk factors for CMV disease in solid organ transplant patients..
Lustberg ME, Ryu JL, Patton J, Quinion C, Baiocchi RA. The immune effects of AR42.
Lustberg ME, Pancholi P, Van Deusen K., Baiocchi RA. Genetic variation in the Epstein Barr Virus (EBV) in those with and without EBV assoicate malignancies.
Alinari L, Yan F, Smith P, Patton J, Quinion C, Yu B, Wu Y, Earl CT, Lustberg ME, et al. PRMT5 Over-Expression is Essential for Epstein-Barr Virus-Driven B-Cell Transformation.